Drug Trial Radar · NCT00175877
A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Mar 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
857
Actual
Start
Jun 2005
Primary completion
Feb 2012
Study completion Feb 2012
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open ended study in which patients who completed the double-blind study CDP870-027 \[NCT00152386\] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).
Conditions
- Rheumatoid Arthritis
Interventions
Certolizumab PegolBiological
Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection. Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks. Duration: Until end of study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 7 YearsTime frame: From first dose of CZP to the end of the open-label study (approximately 7 years)
- Percentage of Subjects With at Least One Serious Adverse Event (SAE) From First Certolizumab Pegol (CZP) Dose up to Approximately 7 YearsTime frame: From first dose of CZP to the end of the open-label study (approximately 7 years)
- Percentage of Subjects Who Withdrew Due to an Adverse Event (AE) During the StudyTime frame: From Entry Visit (Week 0) to the end of the study (approximately 6.5 years)
Locations
121 sites in 22 countries. Site status is shown where the registry gives one.
152
Huntsville, Alabama
148
San Diego, California
153
Danbury, Connecticut
133
Ocala, Florida
140
Orlando, Florida
150
Orlando, Florida
145
Sarasota, Florida
136
Tampa, Florida
157
Coeur d'Alene, Idaho
155
Springfield, Illinois
134
Wheaton, Maryland
151
St Louis, Missouri
156
Lincoln, Nebraska
135
Charlotte, North Carolina
147
Cleveland, Ohio
158
Dayton, Ohio
139
Charleston, South Carolina
137
Austin, Texas
143
San Antonio, Texas
12
Buenos Aires, Argentina
14
Capital Federal, Argentina
1
Capital Federal, Argentina
9
Capital Federal, Argentina
8
Ciudad Autonoma de Buenos Aire, Argentina
11
Córdoba, Argentina
2
Córdoba, Argentina
13
Quilmes, Argentina
7
Rosario, Argentina
10
San Miguel de Tucumán, Argentina
6
Santa Fe, Argentina
18
Malvern, Australia
21
Maroochydore, Australia
23
Perth, Australia
179
Antwerp, Belgium
199
Liège, Belgium
177
Merksem, Belgium
29
Pleven, Bulgaria
221
Sofia, Bulgaria
28
Sofia, Bulgaria
30
Sofia, Bulgaria
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.